Actively Recruiting
Driving Therapeutic Progress of Childhood Leukemia Through Advanced Translational Research With Immediate and Long-term Impact. Precision Medicine for Childhood Leukemia.
Led by Chinese University of Hong Kong · Updated on 2026-02-03
300
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to advance treatment for childhood leukemia, the most common cancer in children. Despite improved outcomes, relapse occurs in 15-40% of cases, often leading to survival rates below 50%. Because increasing standard chemotherapy can cause severe side effects, the study focuses on developing safer, targeted therapies for high-risk patients through two main projects involving genetic analysis and novel antibody development. The first project uses whole-exome and RNA sequencing on children with various types of leukemia to analyze genetic changes and drug sensitivity in samples from blood and bone marrow. The second project develops new antibodies tested in animal models to assess their safety and effectiveness against relapsed or hard-to-treat leukemia. These approaches aim to support precision medicine tailored to each child's leukemia. Participants provide samples for genetic and drug sensitivity testing, which researchers use to identify which patients might benefit from targeted treatments. The study measures include genetic alterations, gene expression, drug sensitivity, and antibody treatment efficacy over up to one year. This research may lead to improved therapies for children with leukemia and has both immediate and long-term goals for treatment progress.
CONDITIONS
Brief Title
Advanced Translational Research on Childhood Leukemia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), mixed phenotype acute leukemia (MPAL), juvenile myelomonocytic leukemia (JMML), or myelodysplastic syndromes (MDS)
- Normal bone marrow donor
- Able to understand English or Chinese
- Age 18 years or younger
- Patient or parent/guardian agrees to participate
You will not qualify if you...
- Unable to understand English or Chinese
- Patient or parent/guardian refuses to participate
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Baseline
Participants provide blood and bone marrow samples for genetic analysis and drug sensitivity testing to understand their leukemia profile.
1 to 2 visits depending on sample collection needs
Duration - Up to 1 year
Participants are monitored through genetic and cytogenetic tests to evaluate disease progression and antibody efficacy over time.
Follow-up visits as scheduled over the year
Trial Site Locations
Total: 1 location
1
Hong Kong Children Hospital
Hong Kong, Hksar, China
Actively Recruiting
Research Team
K
Kathy Chan, Ph. D.
K
Kam Tong Leung, Ph. D.
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here